Meet Andrew Walsh, our VP of Finance. Andrew joined Annovis in December of 2023, as the company began closing out its 3-month Phase 2/3 AD study and 6-month Phase 3 PD study. His appointment was a critical step to ensure that Annovis could build out a robust finance function to continue clinical development of buntanetap program and expand headcount. “The last 8 months since my arrival have been transformative for Annovis, and I have been honored to be a part of such a talented team. My role is focused around fundraising and operational support of our research and clinical activities, so that Annovis can achieve its goal of bringing buntanetap to market for patients,” adds Andrew. See attached profile to learn more about Andrew's recent achievements at Annovis.
Annovis Bio, Inc.
Biotechnology Research
Malvern, Pennsylvania 2,726 followers
It’s time for a new direction in treating Alzheimer’s, Parkinson’s and related neurodegenerative diseases.
About us
Annovis Bio, Inc.’s novel approach to addressing chronic and acute neurodegeneration offers new hope in the fight against the largest unmet need of an aging population. Annovis is a clinical stage, drug platform company focused primarily on drugs for chronic neurodegeneration—AD, its orphan indication AD-DS and PD. Additionally, we have a compound to treat acute neurodegeneration—traumatic brain injury (TBI) and stroke—and a third compound for advanced AD. Our lead compound is ANVS-401, a small, once a day, orally administered, brain penetrant inhibitor of neurotoxic proteins. We believe that ANVS-401 has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration. The biological activity of ANVS-401 has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University and Harvard University. We have also conducted three clinical trials with 125 humans including two safety studies in 120 healthy volunteers and a proof-of-concept study in five MCI patients. These studies showed that ANVS-401 was well tolerated and we saw promising clinical signals: ANVS-401 reduced and normalized the levels of APP, tau and aSYN (aSYN is an unpublished observation), - neurotoxic proteins that are the main cause of neurodegeneration -- back to the levels seen in healthy volunteers and statistically lowered inflammation. We are presently conducting a Phase 2a study in AD patients in collaboration with the Alzheimer Disease Cooperative Study (ADCS) group and plan to initiate a second Phase 2a proof-of-concept study of ANVS-401 in the first quarter of 2020 with 50 PD patients. We believe AD and PD are two of the largest medical needs of the aging U.S. population, and two potentially large markets, once a DMD has been developed and approved. Therefore, we desire to demonstrate ANVS-401's efficacy in both indications.
- Website
-
http://annovisbio.com/
External link for Annovis Bio, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Malvern, Pennsylvania
- Type
- Privately Held
- Founded
- 2008
- Specialties
- Neurodegeneration, Alzheimer’s, Parkinson’s, Alzheimer’s in Down Syndrome, Axonal Transport, Traumatic Brain Injury, APP, tau, aSYN, neurotoxic proteins, APP/Ab (APP), tau/phospho-tau, and a-Synuclein (a-SYN)
Locations
-
Primary
101 Lindenwood Dr.
Suite #225
Malvern, Pennsylvania 19355, US
Employees at Annovis Bio, Inc.
Updates
-
NEWS ALERT! The FDA has approved our new solid form of #buntanetap for future clinical trials targeting #Alzheimer’s and #Parkinson’s diseases! This is a major milestone for us after our recent patent filings and studies. Read more: https://lnkd.in/eabd-k9u
-
Annovis is excited to announce the expansion of its executive team with the addition of four new members. This strategic move comes at a pivotal moment for the company, as the combined expertise and experience of the new hires will play a crucial role in advancing #buntanetap for #Alzheimers and #Parkinsons diseases. Find more details at https://lnkd.in/em6x-RK3
-
As we celebrate Independence Day, Annovis would also like to take this opportunity to share an important milestone for the Parkinson's community! On July 2, the US President signed a bill aimed at tackling Parkinson's disease into law. Titled "Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act", the legislation covers government-wide support to address the disease by forming a Parkinson's advisory committee, which will help coordinate federal efforts toward the united goal. We could not be happier to see this milestone during the same week as we shared our promising Phase III Parkinson's data. The hope is near! https://lnkd.in/exgpNS8E #Parkinsons #PD #Biotech #ParkinsonsDisease"
-
Did you miss yesterday's webcast? Catch up on the most recent Parkinson's Phase III study update followed by a Q&A session from our CEO, Maria L. Maccecchini, PhD, by visiting our YouTube channel https://lnkd.in/e2HkkRSH #Parkinsons #ParkinsonsDisease #Biotech #ClinicalTrials
-
Annovis announces new data from the Phase III study of #buntanetap in #ParkinsonsDisease. The company will host a live webcast today at 4:30pm ET to discuss the study's results. The presentation will be followed by a Q&A. More information can be found at https://lnkd.in/eUWaEQXG To register for the webinar, follow the link https://lnkd.in/g7pKv3CY #Parkinsons #Biotech #ClinicalTrials
-
Annovis Bio files a provisional patent covering manufacturing process for new solid forms of #buntanetap. Learn more at https://lnkd.in/ebNC9b6z #Biotech #Alzheimers #Parkinsons #Innovation
-
Annovis Bio announces the filing of a patent covering new solid forms of #buntanetap with improved properties. Learn more at https://lnkd.in/ezmWdFGF #Biotech #Alzheimers #Parkinsons #Innovation
-
Annovis Bio invites you to an investor webcast on July 2, 2024, at 4:30pm ET. We'll discuss recent #buntanetap advancements from Phase III #Parkinsons study and our strategic plans for future clinical trials. Register now to join us: https://lnkd.in/g7pKv3CY #Biotech #Alzheimers #Parkinsons
-
How exactly does #buntanetap work in a #Parkinsons brain? Buntanetap inhibits the production of alpha-synuclein and other neurotoxic proteins which are major players in driving #neurodegeneration. Learn more about our science at https://lnkd.in/e5g6wB7N